Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

Shelley Wood

March 06, 2024

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Daily News

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

Michael O'Riordan

October 05, 2022

News Daily News

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

Michael O'Riordan

July 19, 2022

News Daily News

Shock in Peripartum Cardiomyopathy Especially Risky in Black, Hispanic Patients

Caitlin E. Cox

July 13, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Todd Neale

October 02, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

ICD Benefit Questioned in Patients With Chronic Kidney Disease

Todd Neale

February 09, 2018

Advertisement

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

Semaglutide Winning Streak Continues in CKD With FLOW

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

Shock in Peripartum Cardiomyopathy Especially Risky in Black, Hispanic Patients

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

FDA Approves Dapagliflozin for CKD Patients

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

ICD Benefit Questioned in Patients With Chronic Kidney Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content